APP to launch Imipenem and Clilastatin, Meropenen in US
APP Pharmaceuticals, a Fresenius Kabi Company, has announced the launch of both Imipenem and Cilastatin for Injection, USP and Meropenem for Injection, USP in the US.
The company will begin the shipment of Meropenem for Injection in 500mg and 1gm single dose vials from 13 February 2012.
The Imipenem and Cilastatin for Injection in 250mg and 500mg single dose vials will be made available in the next three to five weeks, the company said.
Imipenem and Cilastatin for Injection is therapeutically equivalent to the reference-listed drug Primaxin IV, which is currently marketed by Merck.
Meropenem for Injection is therapeutically equivalent to the reference-listed drug Merrem IV, currently marketed by AstraZeneca Pharmaceuticals.
APP Pharmaceuticals president and CEO John Ducker said the upcoming launch of these two products marks APP's entry into the Carbapenem market.
"Adding these two products to our portfolio further strengthens our existing anti-infective line and helps solidify our continued leadership in the reliable supply of sterile generic injectables," Ducker added.
Related Insight
Suppliers Directory
TNT - Clinical Supply Logistics
TNT provides logistics solutions to the clinical research, diagnostic, pharma, bio-tech and med-tech markets (sectors).
Drug Research > Drug Delivery > Suppliers
MPI Research - Drug Safety, Discovery, and Bioanalytical and Analytical Services
MPI Research, with global headquarters in Mattawan, Michigan, provides discovery, safety evaluation, bioanalytical, and analytical services to the biopharmaceutical, medical device, animal health, and chemical industries.
Drug Research > Drug Delivery > Suppliers
Tecnosoft - Monitoring Systems for Temperature, Humidity and Pressure
Tecnosoft is a system development company working for big third party companies while also steering its own product line with its own brand. We have a lot of experience and a great know-how in the medical and geotechnical industry, having developed and produced data acquisition systems for both markets, in Italy and all around the world, for different leading companies.
Drug Research > Drug Delivery > Suppliers
InnoCore Technologies BV – Injectable and Implantable Drug Delivery Products and Drug-Eluting Medical Devices
InnoCore is a drug delivery company providing controlled release systems for the pharmaceutical and medical device industry.
Drug Research > Drug Delivery > Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Delivery Intelligence
Alliance Management at Eurand - Principles and Practices for Driving Winning Partnerships
Published by Aptalis Pharmaceutical Technologies (formerly Eurand)
Drug Research > Drug Delivery > White Papers
Laminar Flow Booths Systems
Published by FPS Food and Pharma Systems Srl
Drug Research > Drug Delivery > White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.